Your browser doesn't support javascript.
loading
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Cramer, Paula; Fürstenau, Moritz; Robrecht, Sandra; Giza, Adam; Zhang, Can; Fink, Anna-Maria; Fischer, Kirsten; Langerbeins, Petra; Al-Sawaf, Othman; Tausch, Eugen; Schneider, Christof; Schetelig, Johannes; Dreger, Peter; Böttcher, Sebastian; Kreuzer, Karl-Anton; Schilhabel, Anke; Ritgen, Matthias; Brüggemann, Monika; Kneba, Michael; Stilgenbauer, Stephan; Eichhorst, Barbara; Hallek, Michael.
Afiliação
  • Cramer P; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. Electronic address: paula.cramer@uk-koeln.de.
  • Fürstenau M; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Robrecht S; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Giza A; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Zhang C; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Fink AM; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Fischer K; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Langerbeins P; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Al-Sawaf O; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Tausch E; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany.
  • Schneider C; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany.
  • Schetelig J; Department I of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Dreger P; Department V of Internal Medicine, University Hospital Heidelberg, Heidelberg, Germany.
  • Böttcher S; Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School, Rostock, Germany.
  • Kreuzer KA; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Schilhabel A; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
  • Ritgen M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
  • Brüggemann M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
  • Kneba M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
  • Stilgenbauer S; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany.
  • Eichhorst B; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Hallek M; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
Lancet Haematol ; 9(10): e745-e755, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35988545
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Antineoplásicos Idioma: En Ano de publicação: 2022 Tipo de documento: Article